Kazuo Hatano
Keio University
48 Papers
205 Citations
Kazuo Hatano is an academic researcher from Keio University. The author has contributed to research in topics: Radiation therapy & Medicine. The author has an hindex of 13, co-authored 48 publications.
Chat about Author
Papers
Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.
Toshihiko Iuchi,Masato Shingyoji,T. Sakaida,Kazuo Hatano,O. Nagano,Meiji Itakura,Hajime Kageyama,Sana Yokoi,Yuzo Hasegawa,K. Kawasaki,Toshihiko Iizasa +10 more
TL;DR: Favorable response of BM to gefitinib even without irradiation was demonstrated and exon 19 deletion was both a predictive and prognostic marker of patients with BM treated by gefITinib.
260
Treatment and prognosis of squamous cell carcinoma of the external auditory canal and middle ear: a multi-institutional retrospective review of 87 patients.
Kazuhiko Ogawa,Katsumasa Nakamura,Kazuo Hatano,Takashi Uno,Nobukazu Fuwa,Jun Itami,Shizuo Kojya,Torahiko Nakashima,Akihiko Shinhama,Takashi Nakagawa,Takafumi Toita,Mitsuhiro Sakai,Takeshi Kodaira,Mikio Suzuki,Hisao Ito,Sadayuki Murayama +15 more
TL;DR: Radical radiotherapy is the treatment of choice for early-stage (T1) diseases, whereas surgery (negative surgical margins if possible) with radiotherapy will be recommended as the standard care for advanced (T2-3) disease.
112
Phase 2 Trial of Hypofractionated High-Dose Intensity Modulated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Newly Diagnosed Glioblastoma
Toshihiko Iuchi,Kazuo Hatano,T. Kodama,T. Sakaida,Sana Yokoi,K. Kawasaki,Yuzo Hasegawa,Ryusuke Hara +7 more
TL;DR: Hypofractionated high-dose IMRT with concurrent and adjuvant TMZ altered the dominant failure pattern from localized to disseminated and prolonged the survival of patients with GBM.
102
Hypofractionated high-dose irradiation for the treatment of malignant astrocytomas using simultaneous integrated boost technique by IMRT.
TL;DR: The authors' regimen of IMRT contributed to the control of both the regional and infiltrating tumors, resulting in better survival of patients.
86
Impact of intraluminal brachytherapy on survival outcome for radiation therapy for unresectable biliary tract cancer: a propensity-score matched-pair analysis.
Yasuo Yoshioka,Kazuhiko Ogawa,Hirobumi Oikawa,Hiroshi Onishi,Naoto Kanesaka,Tetsuro Tamamoto,Takashi Kosugi,Kazuo Hatano,Masao Kobayashi,Yoshinori Ito,Makoto Takayama,Mitsuhiro Takemoto,Katsuyuki Karasawa,Hisayasu Nagakura,Michiko Imai,Yasuhiro Kosaka,Hideya Yamazaki,Fumiaki Isohashi,Kenji Nemoto,Yasumasa Nishimura +19 more
TL;DR: The role of ILBT should be addressed by other measures than survival benefit, for example, by less toxicity, prolonged biliary tract patency decreasing the need for further palliative interventions, or patient quality of life.
35